Bull Selection Strategies Using Genomic Estimated Breeding Values

Larry Schaeffer CGIL, University of Guelph

ICAR-Interbull Meeting Niagara Falls, NY June 18, 2008

Understanding Cancer and Related Topics Understanding SNPs and Cancer



Developed by: Susan Greenhut, M.S. Donna Kerrigan, M.S. Jeanne Kelly Brian Hollen Explains tiny variations in the human genome called Single Nucleotide Polymorphisms (SNPs) that can influence a person's health. Shows how SNPs occur in both coding and noncoding regions and can cause silent, harmless, harmful, or latent effects. Shows how SNPs can be markers for cancer. Suggests that SNPs may also be involved in the different levels of individual cancer risk observed. Suggests that, in the future, SNPs databases may be used to improve cancer diagnosis and treatment planning.

These PowerPoint slides are not locked files. You can mix and match slides from different tutorials as you prepare your own lectures. In the Notes section, you will find explanations of the graphics. The art in this tutorial is copyrighted and **may not** be reused for commercial gain. Please do not remove the NCI logo or the copyright mark from any slide. These tutorials may be copied only if they are distributed free of charge for educational purposes.























History

- Goals
 - 1. Implement whole genome selection
 - 2. QTL detection
- Challenge
 - Needed at least 30,000 good markers
- Problem
 - Product did not exist



SNP Available for Assay [Design
With MAF (18%)	
 Next Generation Sequencing 	62,042
 Bovine HapMap Consortium 	33,836
 DPI, US-MARC, UA 	10,574
InSilico SNPs (72%)	
 Assembly SNP (Filtered) 	278,429
 Baylor Interbreed 	123,049
BAC and BAC-end Derived	89,832
 INRA 	764
Total: 598,648 85% Infinium II	(1 Bead)
15% Infinium I	(2 Beads)













- SNP interval estimates deteriorate over time
- Effects need to be re-estimated
- Estimates differ between populations
- SNP panels will change over time













Schen	ne A:
Cori	(GEBV,TBV)
year	ncreasing from 0.4 to 0.8, no change in GSD per — about 0.34.
N I	
Nun	ber of Young Bulls Genotyped
Nun	ber of Young Bulls Genotyped More is better, balance against costs
Nun Nun	nber of Young Bulls Genotyped More is better, balance against costs nber Chosen for PT (400 – 200 – 100)
Nun	nber of Young Bulls Genotyped More is better, balance against costs nber Chosen for PT (400 – 200 – 100) No drop in GSD, costs decrease to \$6.1 M for 100

B: Use Young Bulls as Sire of Sons

Genotype 500-4000 young bulls at birth, GEBV Select 50, best 20 as Sires of Sons for next generation

Cost of purchasing a bull = \$20,000 Special contracts may be needed

Scheme B: Time Frame

Year 0 – young bull is born AND GENOTYPED, GEBV

- Year 1 Use as though a proven sire, sire of sons
- Year 2 -
- Year 3 -
- Year 4 –
- Year 5 young bulls receive usual first proof

0 years from birth to proof, no need to wait 6 years









Results

- Genotype 2000 bulls per year, GEBV
- Reduce number for PT to 100-200
- Use top 10 as Sires of Sons
- Gradually phase out PT and go to Scheme B
- Share SNP results with world



- Genotype at birth, GEBV
- Use top 5000 as dams of bulls
- Use top cows as herd replacements
- No point in genotyping current dams of bulls already known entities.
- GEBV better than EBV no pref trt.

Conclusions

- Use GEBV to select, and use young animals as though they were proven
- Costs may increase for young animals
- Inbreeding should be studied
- Strategies for producers to be involved
- International implications (share or not)



